Background: Health inequalities remain a major public health challenge in England, with people living in more deprived areas experiencing poorer outcomes. Although SGLT2 inhibitors (SGLT2i) are clinically and cost-effective for type 2 diabetes mellitus (T2DM) and related cardiovascular and renal conditions, little is known about how their health benefits are distributed across deprivation groups. We examined the distribution of health benefits associated with SGLT2i across deprivation and clinical subgroups, and the implications for health inequalities.Methods: We used data from a 2023 cross-sectional analysis of the Clinical Practice Research Datalink (CPRD), linked to Hospital Episodes Statistics (HES) and small-area deprivation data in England. T2DM prevalence and selected comorbidities and SGLT2i uptake were estimated across deprivation quintiles. A distributional cost-effectiveness analysis was used to estimate total and net health benefits (QALYs) and opportunity costs. Scenario analyses examined increased uptake and alternative distributions of opportunity costs.Findings: T2DM and associated comorbidities were more prevalent in more deprived areas across all subgroups. SGLT2i uptake varied modestly by deprivation but more substantially across clinical subgroups. SGLT2i generated positive net health benefits across all groups, with the largest gains accruing to more deprived populations, reflecting disease burden and baseline risk. Increasing uptake increased health gains, with similar distributional patterns across deprivation groups.Interpretation: SGLT2i generate substantial net health benefits across all deprivation groups, with the greatest gains in more deprived populations. Improving uptake represents an important opportunity to improve population health while reducing health inequalities.